BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16325969)

  • 21. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.
    Carrión J; Folgueira C; Alonso C
    Vaccine; 2008 May; 26(20):2537-44. PubMed ID: 18400342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P; Saxena S; Madhubala R
    Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.
    Rafati S; Salmanian AH; Taheri T; Vafa M; Fasel N
    Vaccine; 2001 May; 19(25-26):3369-75. PubMed ID: 11348700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes.
    Afrin F; Anam K; Ali N
    J Parasitol; 2000 Aug; 86(4):730-5. PubMed ID: 10958448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis.
    Nagill R; Mahajan R; Sharma M; Kaur S
    Parasitol Int; 2009 Dec; 58(4):359-66. PubMed ID: 19638322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
    Agallou M; Smirlis D; Soteriadou KP; Karagouni E
    Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S; Mazumdar T; Sinha R; Ali N
    J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.
    Iborra S; Soto M; Carrión J; Nieto A; Fernández E; Alonso C; Requena JM
    Infect Immun; 2003 Nov; 71(11):6562-72. PubMed ID: 14573678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
    Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice.
    Streit JA; Recker TJ; Donelson JE; Wilson ME
    Exp Parasitol; 2000 Jan; 94(1):33-41. PubMed ID: 10631078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
    Carson C; Antoniou M; Ruiz-Argüello MB; Alcami A; Christodoulou V; Messaritakis I; Blackwell JM; Courtenay O
    Vaccine; 2009 Feb; 27(7):1080-6. PubMed ID: 19095029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection.
    Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Taslimi Y; Vahabpour R; Torkashvand F; Vaziri B; Rafati S
    J Control Release; 2011 Jul; 153(2):154-62. PubMed ID: 21530597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.